María del Rosario
García Campelo
![Foto de María del Rosario](/img/nophoto.png)
![Foto de University Hospital of Bern](/img/noimage_org.png)
University Hospital of Bern
Berna, SuizaPublicacións en colaboración con investigadores/as de University Hospital of Bern (1)
2022
-
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
Annals of Oncology, Vol. 33, Núm. 2, pp. 181-192